Efficacy and safety of sirolimus-eluting stents versus bare-metal stents in coronary artery disease patients with diabetes: A meta-analysis

Cardiovascular Journal of Africa

Volumn 24, Issue 7, 2013, Pages 274-279

  Qiao, Yanxiang ^a   Bian, Yuan ^a   Yan, Xianliang ^a   Liu, Zhenfang ^a   Chen, Yuguo ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Bare metal stent; Diabetes; Efficacy; Meta analysis; Safety; Sirolimus eluting stent

Indexed keywords

RAPAMYCIN;

ARTICLE; BARE METAL STENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COCHRANE LIBRARY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; EMBASE; GEOGRAPHIC DISTRIBUTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; RISK REDUCTION; SAMPLE SIZE; SENSITIVITY ANALYSIS;

CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; HUMANS; METALS; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT SAFETY; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 84889262252     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2013-062     Document Type: Article

References (36)

1. Nodari S, Manerba A, Vaccari A, Milesi G, Carubelli V, Lazzarini V, et al. Six-year prognosis of diabetic patients with coronary artery disease. Eur J Clin Invest 2012; 42(4): 376-383.
2. Van Nunen LX, Tonino PA. Recent insights into the treatment of stable CAD: FFR-guided PCI vs. medical therapy. Herz 2013. 2013 Apr 17. [Epub ahead of print].
3. Haase J, Jung T, Störger H, Hofmann M, Reinemer H, Schwarz CE, et al. Long-term outcome after implantation of bare metal stents for the treatment of coronary artery disease: rationale for the clinical use of antiproliferative stent coatings. J Interv Cardiol 2003; 16(6): 469-473. (Pubitemid 37431013)
4. Lemos PA, Bienert I. The Supralimus® sirolimus-eluting stent. Expert Rev Med Devices 2013. 2013 Apr 18. [Epub ahead of print].
5. Hsieh IC, Chang SH, Wang CY, Lee CH, Lin FC, Chen CC. Acute and long-term outcomes of ostial stentings among bare-metal stents, sirolimus-eluting stents, and paclitaxel-eluting stents. Coron Artery Dis 2013; 24(3): 224-230.
6. Obata JE, Nakamura T, Kitta Y, Saito Y, Sano K, Fujioka D, Kawabata KI, et al. In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter. Catheter Cardiovasc Interv 2013. 2013 Feb 4. doi: 10.1002/ccd.24841. [Epub ahead of print].
7. Otake H, Honda Y, Courtney BK, Shimohama T, Ako J, Waseda K, Macours N, et al. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimuseluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions. Circ Cardiovasc Interv 2011; 4(2): 146-154.
8. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Costa MA, Alfonso F, Gómez-Hospital JA, Hernández-Antolín R, et al.; DIABETES Investigators. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006; 47(11): 2172-2179. (Pubitemid 43795082)
9. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, et al.; DESERT Cooperation. Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to baremetal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. Am J Cardiol 2013; 111(9): 1295-1304.
10. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, Williams DO, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. Br Med J 2012; 345: e5170.
11. Sinning JM, Baumgart D, Werner N, Klauss V, Baer FM, Hartmann F, Drexler H, et al.; SCORPIUS Study. Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Am Heart J 2012; 163(3): 446-453.
12. Aoki J, Ong A, Rodriguez-Granillo G, Van Mieghem C, Daemen J, Sonnenschein K, McFadden E, et al. The efficacy of sirolimus-eluting stents versus bare metal stents for diabetic patients undergoing elective percutaneous coronary intervention. J Invasive Cardiol 2005; 17(7): 344-348.
13. Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, Sangiorgio P, et al.; DESSERT Investigators. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol 2008; 101(11): 1560-1566.
14. Chan C, Zambahari R, Kaul U, Lau CP, Whitworth H, Cohen S, Buchbinder M; DECODE investigators. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study. Catheter Cardiovasc Interv 2008; 72(5): 591-600.
15. Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H, et al.; SCORPIUS study investigators. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 2007; 50(17): 1627-1634. (Pubitemid 47562680)
16. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007; 28(1): 26-32. (Pubitemid 46134954)
17. DerSimonian R. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-188. (Pubitemid 17189972)
18. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med 1996 15(12): 1237-1248.
19. Klebanoff MA, Levine RJ, DerSimonian R. Large trials vs meta-analysis of smaller trials. J Am Med Assoc 1997; 277(5): 376-377.
20. Geller N, Freedman L, Lee YJ, DerSimonian R. Conference on meta-analysis in the design and monitoring of clinical trials. Stat Med 1999; 18(6): 753-754.
21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
22. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J 2011; 343: D4002.
23. DerSimonian R, Levine RJ. Resolving discrepancies between a meta-analysis and a subsequent large controlled trial. J Am Med Assoc 1999; 282(7): 664-670. (Pubitemid 29384155)
24. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28(2): 105-114. (Pubitemid 44937874)
25. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. Br Med J 2011; 342(d549).
26. Moreno SG, Sutton AJ, Thompson JR, Ades AE, Abrams KR, Cooper NJ. A generalized weighting regression-derived meta-analysis estimator robust to small-study effects and heterogeneity. Stat Med 2012; 31(14): 1407-1417.
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-1558. (Pubitemid 34746062)
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315(7109): 629-634. (Pubitemid 27387172)
29. Jiménez-Quevedo P, Hernando L, Gómez-Hospital JA, Iñiguez A, Sanroman A, Alfonso F, Hernández-Antolín R, et al. Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial. EuroIntervention 2013; 2013 Mar 22. pii: 20120620-01. [Epub ahead of print].
30. Galassi AR, Tomasello SD, Costanzo L, Campisano MB, Barrano G, Tamburino C. Long-term clinical and angiographic results of Sirolimus-Eluting Stent in Complex Coronary Chronic Total Occlusion Revascularization: the SECTOR registry. J Interv Cardiol 2011; 24(5): 426-436.
31. De Waha A, Dibra A, Kufner S, Baumgart D, Sabate M, Maresta A, Schömig A, Kastrati A. Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. Clin Res Cardiol 2011; 100(7): 561-570.
32. Kandzari DE, Rao SV, Moses JW, Dzavik V, Strauss BH, Kutryk MJ, Simonton CA, et al; ACROSS/TOSCA-4 investigators. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. J Am Coll Cardiol Cardiovasc Interv 2009; 2(2): 97-106.
33. Byrne RA, Kastrati A. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. Catheter Cardiovasc Interv 2008; 72(7): 944-949.
34. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21(11): 1559-1573. (Pubitemid 34746063)
35. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54(10): 1046-1055. (Pubitemid 32888370)
36. Zwahlen M, Renehan A, Egger M. Meta-analysis in medical research: potentials and limitations. Urol Oncol 2008; 26(3): 320-329. (Pubitemid 351608570)